YOD1

Across TCGA pan-cancer cohorts, YOD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated YOD1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher YOD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated YOD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and UCEC are the cancer types where YOD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.246	0.541	.025	18	view →
BLCA	OS	Median	All	0.228	0.720	.010	18	view →
UCEC	DFS	Median	All	0.969	0.621	.006	18	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

YOD1–OV (DFS)

Open the OV breakdown →